Biopharmaceutics Classification System

For other uses of the abbreviation BCS, see BCS (disambiguation).

The Biopharmaceutics Classification System is a system to differentiate the drugs on the basis of their solubility and permeability. It is a guide for predicting the intestinal drug absorption provided by the U.S. Food and Drug Administration[1]. The fundamental basis for the BCS was established by Gordon Amidon, who was presented with a Distinguished Science Award at the August 2006 International Pharmaceutical Federation (FIP) congress in Salvador, Brazil.

This system restricts the prediction using the parameters solubility and intestinal permeability. The solubility classification is based on a United States Pharmacopoeia (USP) aperture. The intestinal permeability classification is based on a comparison to the intravenous injection. All those factors are highly important because 85% of the most sold drugs in the United States and Europe are orally administered.

See also

• ADME
  • Partition coefficient
  • Bioavailability
  • Drug metabolism
  • First pass effect
• Polar surface area
• IVIVC

References

• Folkers, Gerd; van de Waterbeemd, Han; Lennernäs, Hans; Artursson, Per; Mannhold, Raimund; Kubinyi, Hugo (2003). Drug Bioavailability: Estimation of Solubility, Permeability, Absorption and Bioavailability (Methods and Principles in Medicinal Chemistry). Weinheim: Wiley-VCH. ISBN 3-527-30438-X. {{cite book}}: Unknown parameter |name-list-format= ignored (|name-list-style= suggested) (help)
• Amidon GL, Lennernäs H, Shah VP, Crison JR (March 1995). "A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability". Pharm. Res. 12 (3): 413–20. PMID 7617530.

External links

• BCS guidance of the U.S. Food and Drug Administration